NCT01612767已完成2 期
The Treatment of Coronary Artery Lesions Using the PRO-Kinetic Energy Cobalt-Chromium, Bare-Metal Stent
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 329
- 试验地点
- 35
- 主要终点
- Target Vessel Failure Rate
研究概览
简要总结
The purpose of this study is to demonstrate the safety and efficacy of the investigational BIOTRONIK PRO-Kinetic Energy stent in subjects with atherosclerotic disease of native coronary arteries.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •For a subject to be enrolled in the study and considered for the index procedure, the following initial inclusion criteria must be met:
- •Age ≥ 18 years
- •Willingness to comply with study follow-up requirements
- •Candidate for a percutaneous coronary intervention (PCI) procedure
- •Candidate for coronary artery bypass graft surgery
- •Documented evidence of stable or unstable angina pectoris or positive functional ischemia study (e.g. exercise treadmill test, thallium stress test, SPECT, stress echocardiogram or cardiac CT) Stable angina pectoris is defined as a documented Canadian Cardiovascular Society Classification of I, II, III or IV Unstable angina pectoris is defined as a documented Braunwald Classification of B & C, I, II, III
- •Written informed consent
- •For a subject to receive an investigational stent, the following procedure-related criteria must be met:
- •De novo or restenotic lesion in a native coronary artery; restenotic lesions must have been previously treated with only standard percutaneous transluminal coronary angioplasty (PTCA) (treatment must be > 12 months prior to the index procedure)
- •Target lesion must be in a major coronary artery (target vessel). The target vessel includes the entire territory of the left anterior descending artery, left circumflex artery or right coronary artery and any major side branch of the artery.
- •A maximum of one target lesion and one non-target lesion may be treated per subject. The lesions must be located in separate coronary arteries, with treatment of the non-target lesion occurring first using commercially available therapy (with exception of brachytherapy).
- •Lesions may be one solid lesion or a series of multiple, smaller lesions to be treated as one lesion
- •Target lesion must be treatable with a single investigational stent; an additional stent may be used when treating a vessel dissection or another similar intra-procedure complication (use of investigational stent preferred)
- •Angiographic evidence of ≥ 50% and < 100% stenosis (by operator visual estimate) with a TIMI flow > 1
- •Target lesion length of ≤ 31 mm by operator visual estimate
- •Target vessel reference diameter of 2.25 mm to 4.0 mm by operator visual estimate
排除标准
- •For a subject to be enrolled in the study and considered for the index procedure, the following initial exclusion criteria must not be present:
- •Baseline LVEF of < 30%; LVEF may be measured and assessed by standard-of-care echocardiography procedures within 90 days of the index procedure or by a left ventriculogram prior to the index procedure (operator visual assessment).
- •PCI in any vessel 30 days prior to the index procedure or planned for within 30 days after the index procedure
- •Stroke or transient ischemic attack within the last 6 months prior to enrollment
- •Intolerance to contrast agents that cannot be medically managed and/or intolerance to antiplatelet, anticoagulant or thrombolytic medications
- •Refusal of blood transfusions
- •Any other medical condition, that in the opinion of the investigator, poses an unacceptable risk for implant of a stent according to the study indications
- •Pregnant, planning to become pregnant or nursing during the course of the study. Women of child-bearing potential must have a negative blood pregnancy (beta hCG) test. Female subjects who are surgically sterile or post-menopausal are exempt from having a pregnancy test.
- •Known allergy to L-605 CoCr alloy (cobalt, chromium, tungsten and nickel) or amorphous silicon carbide
- •Life expectancy of less than one year
- •Participation in any other clinical investigational device or drug study.
- •Subjects may be concurrently enrolled in a post-market study, as long as the post-market study device, drug or protocol does not interfere with the investigational treatment or protocol of this study.
- •For a subject to receive an investigational stent the following procedure-related criteria must not be present:
- •Documented diagnosis of an acute MI within 72 hours of the index procedure and an elevation of Troponin or creatine kinase-MB (CKMB) above the URL (CKMB measurement is not required if CK is normal) at the time of the index procedure (99th percentile of the individual investigative site's normal reference population)
- •For subjects with stable angina and elevated Troponin, CKMB <99% URL is required
- •ECG changes consistent with an acute MI within 72 hours of the index procedure. ECG changes consistent with an acute MI include:
- •> 1 mm ST segment elevation or depression in consecutive leads New left bundle branch block (LBBB) Development of pathological Q-waves in two contiguous leads of the electrocardiogram (ECG)
- •Acute coronary syndrome with baseline Troponin > 99% URL
- •INR ≥ 1.6
- •Concomitant renal failure with serum creatinine level > 2.5 mg/dL
- •Unresolved neutropenia (white blood cell count < 3,000 / µL), thrombocytopenia (platelet count < 100,000 / µL) or thrombocytosis (platelet count > 700,000 / µL)
- •Unprotected left main coronary artery disease (CAD) (> 50% diameter stenosis by operator visual estimate)
- •Target vessel has been treated with any PCI procedure (e.g. PTCA, stent, cutting balloon, atherectomy, etc.) within 12 months prior to the index procedure
- •Target lesion has been treated with a stent, cutting balloon or atherectomy any time prior to the index procedure or has been treated with PTCA within 12 months prior to the index procedure
- •Target vessel treated with brachytherapy anytime prior to index procedure
- •Planned PCI in the target vessel within 9 months after the index procedure
- •Target vessel has a non-target lesion with a > 50% stenosis that requires treatment during the index procedure
- •Lesions preventing distal perfusion (TIMI flow 0 and 1) prior to wire crossing
- •Target lesion is in the left main coronary artery or within 2 mm of the origin of the left anterior descending artery or left circumflex artery by operator visual estimate
- •Target lesion is located within a saphenous vein graft or arterial graft
- •Target lesion involves a bifurcation - lesion is located in a major coronary artery and involves a side branch with a diameter > 2 mm (by operator visual estimate)
- •Presence of a complication following pre-dilatation of target lesion
- •Presence of a complication following treatment of a non-target lesion (if applicable)
- •Presence of a target vessel/lesion that has excessive tortuousity/angulation or is severely calcified preventing complete inflation of an angioplasty balloon
- •Angiographic evidence of thrombus within the target lesion
- •Target lesion is located within an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion
- •Use of cutting balloons, atherectomy or ablative devices immediately prior to investigational stent placement
研究组 & 干预措施
Pro-Kinetic Energy Stent
Experimental
干预措施: PRO-Kinetic Energy Stent (Device)
结局指标
主要结局
Target Vessel Failure Rate
时间窗: 9 months post-index procedure
The primary endpoint for the Pro-Kinetic Energy Stent is the target vessel failure rate at 9-months post-index procedure. Target vessel failure is defined as cardiac death, myocardial infarction and ischemia-driven target vessel revascularization.
次要结局
- Target Vessel Failure Rate(1, 12, 24 and 36 months post-index procedure)
- Target Vessel Failure Rate - Contribution of Individual Event Types(1, 12, 24 and 36 months post-index procedure)
- Overall Target Vessel Revascularization Rate(1, 9, 12, 24 and 36 months post-index procedure)
- Overall Target Lesion Failure Rate(1, 9, 12, 24 and 36 months post-index procedure)
- Target Lesion Failure Rate - Contribution of Individual Event Types(1, 9, 12, 24, and 36 months post-index procedure)
- Composite of All-cause Mortality and All-cause MI(1, 9, 12, 24, and 36 months post-index procedure)
- All-cause Mortality and All-cause MI - Contribution of Individual Rates(1, 9, 12, 24, and 36 months post-index procedure)
- Stent Thrombosis Rate(1, 9, 12, 24 and 36 months post-index procedure)
- Overall Target Lesion Revascularization Rate(1, 9, 12, 24 and 36 months post-index procedure)
- Index Procedure Success(Index procedure)
- Device Success During the Index Procedure(Index procedure)
- Lesion Success During the Index Procedure(Index procedure)
- Angina Pectoris Classification(Basline, Discharge, 1, 9, 12, 24 and 36 months post-index procedure)
研究者
研究点 (35)
Loading locations...
相似试验
终止
不适用
The Treatment of Coronary Artery Lesions Using the PRO-Kinetic Energy Cobalt-Chromium, Bare-Metal StentCoronary Artery DiseaseNCT01811927Biotronik AG43
已完成
2 期
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar StentsPeripheral Artery DiseasePeripheral Vascular DiseaseNCT01319812Biotronik, Inc.463
Unknown
不适用
BIOTRONIK - BIOFLOW-III Registry French SatelliteCoronary Artery DiseasesNCT02273648Biotronik France1,000
招募中
不适用
Intracoronary Stenting and Additional Results Achieved by ShockWAVE Coronary LithotripsyCoronary Artery DiseaseNCT06369142Deutsches Herzzentrum Muenchen666
已完成
不适用
A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary In-stent RestenosisCoronary In-stent RestenosisNCT03373695DK Medical Technology (Suzhou) Co., Ltd.260